Idiopathic Pulmonary Fibrosis Treatment Market Segmentation:
Route of Administration (Oral, Parenteral)
Based on the route of administration, the oral segment is projected to register a significant share in the idiopathic pulmonary fibrosis treatment market during the forecast period. This is due to its convenience, ease of use, and patient preference. Oral medications are widely used as they allow patients to manage their condition with less frequent hospital visits compared to injectable options. Additionally, oral therapies support better adherence, which is crucial in managing a chronic condition like IPF, where long-term treatment is necessary to slow disease progression. In October 2023, Bristol Mayers Squibb received U.S. FDA approval for a potential first-in-class, oral medication for people living with IPF and PPF.
End use (Hospitals and Clinics, Ambulatory Surgical Centers (ASCs), Homecare Settings)
Based on end use, hospitals and clinics segment is set to capture IPF treatment market share of over 50.6% by 2035. Hospitals play a critical part in supervising acute exacerbations of IPF and offer intensive care throughout disease progression. Meanwhile, specialty clinics offer personalized care approaches, including advanced treatments such as antifibrotic drugs and several emerging gene therapies. These healthcare facilities have the necessary resources and trained medical staff to administer complex therapies and ensure patients receive optimal care.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
Route of Administration |
|
|
Age Group |
|
|
End use |
|
